Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.63 |
| ▸ | HTR1A | P08908 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31051951 | 0.85 | ADRB1 (0.65) | ADRB1HTR1AALDH1A1LMNACYP3A4 | |
| SCHEMBL31051821 | 0.84 | ADRB1 (0.63) | ADRB1HTR1AALDH1A1LMNACYP3A4 | |
| SCHEMBL31051831 | 0.84 | ADRB1 (0.63) | ADRB1HTR1AALDH1A1LMNACYP3A4 | |
| SCHEMBL31052160 | 0.84 | ADRB1 (0.63) | ADRB1HTR1AALDH1A1LMNACYP3A4 | |
| SCHEMBL31052205 | 0.83 | ADRB1 (0.63) | ADRB1HTR1AALDH1A1LMNACYP3A4 | |
| SCHEMBL31051772 | 0.83 | ADRB1 (0.43) | ADRB1HTR1AALDH1A1LMNACYP3A4 | |
| SCHEMBL31051981 | 0.83 | ADRB1 (0.43) | ADRB1HTR1AALDH1A1LMNACYP3A4 | |
| SCHEMBL31052118 | 0.83 | ADRB1 (0.57) | ADRB1HTR1AALDH1A1LMNACYP3A4 | |
| SCHEMBL31052277 | 0.81 | ADRB1 (0.59) | ADRB1HTR1AALDH1A1LMNACYP3A4 | |
| SCHEMBL31052244 | 0.80 | DRD2 (0.65) | ADRB1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678188-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING, OR MANAGING BILIRUBIN-INDUCED NEUROLOGICAL DYSFUNCTION, PSYCHIATRIC DISORDERS ASSOCIATED WITH JAUNDICE, OR PSYCHIATRIC DISORDERS CAUSED BY BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE GENE MUTATIONS | Ohnishi, Arata (JP) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024185842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING, OR MANAGING BILIRUBIN-INDUCED NEUROLOGICAL DYSFUNCTION, PSYCHIATRIC DISORDERS ASSOCIATED WITH JAUNDICE, OR PSYCHIATRIC DISORDERS CAUSED BY BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE GENE MUTATIONS | 国立大学法人島根大学 | 2024-09-12 | — | — | WO | disclosed |